Low-dose lithium mono- and adjunctive therapies improve MK-801-induced cognitive impairment and schizophrenia-like behavior in mice - Evidence from altered prefrontal lobe Ca2+ activity
Journal of Affective Disorders · 2023
DOI: 10.1016/j.jad.2023.05.069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2023. Verfasst von Chuanjun Zhuo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Sensory Information Processing Abnormalities in Schizophrenia (SIPAS-Lab), Nankai University Affiliated Tianjin Fourth Center Hospi…. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents, Cognitive Dysfunction. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 88 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Few studies have evaluated lithium either as monotherapy or in combination with anti-psychotic agents to improve cognition in murine models of schizophrenia. METHODS: Visualization of Ca2+ activity in the prefrontal cortex was used to characterize brain neural activity. Novel object recognition (NOR), Morris water maze (MWM), and fear conditioning (FCT) tests were used to characterize cognitive performance; while pre-pulse inhibition (PPI), elevated plus maze (EPM) and the open field test (OFT) were used to characterize schizophrenia-like behavior. RESULTS: A 28-day course of low-dose lithium (human equivalent dose of 250 mg/day) combined with moderate-dose quetiapine (human equivalent dose of 600 mg/day) improved Ca2+ ratio by 70.10 %, PPI by 69.28 %, NOR by 70.09 %, MWM by 71.28 %, FCT by 68.56 %, EPM by 70.95 % and OFT by 75.23 % compared to the results of positive controls. Unexpectedly, moderate-dose lithium (human equivalent dose of 500 mg/day) used either as monotherapy or as an adjunct with quetiapine worsened Ca2+ activity, PPI, MWM, FCT, EPM, and OPT. LIMITATIONS: Our study cannot explain the contrasting positive and negative effects of low-dose and moderate-dose lithium, respectively, when used either as monotherapies or as adjuncts. Further studies, especially Western blotting, may reveal molecular mechanisms of action. CONCLUSIONS: Low-dose lithium (human equivalent dose of 250 mg/day) combined with moderate-dose quetiapine (human equivalent dose of 600 mg/day) provided the best improvements. Furthermore, benefits persisted for 14 days post-treatment. Our data provide directions for further research of therapeutic alternatives to mitigate schizophrenia-related cognopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Sensory Information Processing Abnormalities in Schizophrenia (SIPAS-Lab), Nankai University Affiliated Tianjin Fourth Center Hospital, Tianjin Medical University Affiliated Tianjin Fourth Center Hospi…
- Animal Micro-imaging Center (AMC) of TJ4CH-WZ7PH Joint Mental Health Institute, Wenzhou Seventh Peoples Hospital, Wenzhou 325000, China.
- Laboratory of Psychiatric-Neuroimaging-Genetic and Co-morbidity (PNGC-Lab), Tianjin Mental Health Center of Tianjin Medical University, Nankai University Affiliated Tianjin Anding Hopsital, Tianjin Anding Hospital, Tian…
- Department of Psychiatry, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Henan International Joint Laboratory of Biological Psychiatry, Zhengzhou, China; Henan Psychiatric Transformation Resear…
- Animal Micro-imaging Center (AMC) of TJ4CH-WZ7PH Joint Mental Health Institute, Wenzhou Seventh Peoples Hospital, Wenzhou 325000, China. Electronic address: langlangchengwzmh@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhuo, C., Tian, H., Chen, G., Ping, J., Yang, L., Li, C., Zhang, Q., Wang, L., Ma, X., Li, R., Sun, Y., Song, X., & Cheng, L. (2023). Low-dose lithium mono- and adjunctive therapies improve MK-801-induced cognitive impairment and schizophrenia-like behavior in mice - Evidence from altered prefrontal lobe Ca2+ activity. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2023.05.069
Vancouver
Zhuo C, Tian H, Chen G, Ping J, Yang L, Li C, et al. Low-dose lithium mono- and adjunctive therapies improve MK-801-induced cognitive impairment and schizophrenia-like behavior in mice - Evidence from altered prefrontal lobe Ca2+ activity. Journal of Affective Disorders. 2023. doi:10.1016/j.jad.2023.05.069
BibTeX
@article{Zhuo2023,
author = {Zhuo, Chuanjun and Tian, Hongjun and Chen, Guangdong and Ping, Jing and Yang, Lei and Li, Chao and Zhang, Qiuyu and Wang, Lina and Ma, Xiaoyan and Li, Ranli and Sun, Yun and Song, Xueqin and Cheng, Langlang},
title = {Low-dose lithium mono- and adjunctive therapies improve MK-801-induced cognitive impairment and schizophrenia-like behavior in mice - Evidence from altered prefrontal lobe Ca2+ activity},
journal = {Journal of Affective Disorders},
year = {2023},
doi = {10.1016/j.jad.2023.05.069}
}
EUVIMED